Pfizer has said its booster shot will offer further protection, but it has not yet been approved by authorities.
On June 29, 2021, The British Medical Journal (BMJ) reported that prolonging the gap between the first and second treatment to 45 weeks resulted in more significant antibody titers. They also discovered that giving a third dosage 44 to 45 weeks after the second treatment boosted antibody titers and that side effects were lower after the second or third dose than after the first.
According to a press release by BioNTech on July 8, 2021, Pfizer and BioNTech have received positive evidence in the ongoing booster trial for a third dosage of the existing BNT162b2 vaccine. The study's preliminary findings showed that a booster dosage given six months after the second dose has a consistent tolerability profile. It also produces strong neutralization titers against the wild type and the Beta variant, which are 5 to 10 times higher than after two initial doses.
According to Reuters, Pfizer is about to seek U.S. authorization for a third dosage for its COVID-19 vaccine. On July 8, 2021, claiming that another shot within a year might significantly enhance protection and possibly help stave off the next worrying coronavirus mutation.
On April 1, 2021, the Wall Street Journal (WSJ) reported that corporations and other vaccine researchers were unable to establish the necessity of booster shots and whether it would assure protection from new variants.
On January 29, 2021, the BMJ reported that a series of vaccination price discoveries have heightened awareness of a practice common in the pharmaceutical sector but frowned upon elsewhere: charging different prices to different clients for the same product. The European Union funded BioNTech and Pfizer's vaccine development and achieved lower per-dose pricing ($14.70) than the United States ($19.50). The U.S. government-financed the development of the Moderna vaccine, and it would cost roughly $15 per dosage in the U.S., but it will cost $18 in the EU.
However, there is no evidence for Pfizer's third dose price as the company and other medical governing bodies are yet to be authorized.
The COVID-19 pandemic has given rise to a lot of potentially dangerous misinformation. For reliable advice on COVID-19, including symptoms, prevention, and available treatment, please refer to the World Health Organization or your national healthcare authority.